XML 37 R27.htm IDEA: XBRL DOCUMENT v3.25.3

Industry Segment Information (Tables)

9 Months Ended

Sep. 28, 2025

Segment Reporting [Abstract]

Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations

Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  

			Three Months Ended
			September 28, 2025																		September 29, 2024
			Life Sciences						Diagnostics						Total						Life Sciences						Diagnostics						Total
			(In thousands)
Segment revenue			$	342,822					$	356,127					$	698,949					$	338,800					$	345,249					$	684,049
Segment cost of revenue			129,976						158,900												117,546						144,653
Segment selling, general and administrative expenses			84,190						84,719												84,944						84,116
Segment research and development expenses			27,608						23,132												25,745						22,632
Segment operating income			$	101,048					$	89,376					190,424						$	110,565					$	93,848					204,413
Corporate expenses															(8,008)																		(10,915)
Amortization of intangible assets															(84,074)																		(89,642)
Purchase accounting adjustments															(348)																		(103)
Acquisition and divestiture-related costs															(284)																		(4,874)
Transformation costs															(5,103)																		—
Significant litigation matters and settlements															(785)																		(810)
Restructuring and other, net															(9,926)																		82
Interest and other (expense) income, net															(26,211)																		2,206
Income from continuing operations before income taxes															$	55,685																	$	100,357

			Nine Months Ended
			September 28, 2025																		September 29, 2024
			Life Sciences						Diagnostics						Total						Life Sciences						Diagnostics						Total
			(In thousands)
Segment revenue			$	1,049,115					$	1,034,880					$	2,083,995					$	1,023,839					$	1,001,815					$	2,025,654
Segment cost of revenue			384,325						450,130												361,534						421,836
Segment selling, general and administrative expenses			258,271						258,736												255,048						249,996
Segment research and development expenses			84,291						73,201												78,174						67,182
Segment operating income			$	322,228					$	252,813					575,041						$	329,083					$	262,801					591,884
Corporate expenses															(30,912)																		(33,725)
Amortization of intangible assets															(252,063)																		(271,500)
Purchase accounting adjustments															(2,349)																		(7,348)
Acquisition and divestiture-related costs															(2,950)																		(22,115)
Transformation costs															(6,226)																		—
Significant litigation matters and settlements															(12,495)																		(7,086)
Significant environmental matters															1,208																		—
Restructuring and other, net															(24,368)																		(22,119)
Interest and other expense, net															(68,169)																		(6,423)
Income from continuing operations before income taxes															$	176,717																	$	221,568

Schedule of Depreciation [Table Text Block]

Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
			(In thousands)
Life Sciences			$	8,456					$	8,674					$	24,188					$	25,068
Diagnostics			8,785						8,839						23,910						24,540
Corporate			744						516						2,100						1,708
Total depreciation expense			$	17,985					$	18,029					$	50,198					$	51,316

X

- Definition

Schedule of Depreciation

+ References

No definition available.

+ Details

Name:	revv_ScheduleOfDepreciationTableTextBlock
Namespace Prefix:	revv_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration